Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
| The Manila Times
Breakthrough Therapy Designation granted for pevifoscorvir sodium in China
Ähnliche Seiten
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection - PubMed
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
| The Manila Times
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
| The Manila Times